At what HbA1c level can neuropathy occur is a question many people with diabetes — and their clinicians — rightly ask. HbA1c (glycated haemoglobin), measured in mmol/mol in the UK, reflects average blood glucose over two to three months and is a key predictor of diabetic nerve damage. There is no single threshold at which neuropathy suddenly begins; rather, risk accumulates progressively with sustained elevation above the normal range. Understanding this relationship, alongside NICE-recommended targets and early warning signs, is essential for preventing and managing diabetic peripheral neuropathy effectively.

How HbA1c Levels Relate to Nerve Damage in Diabetes

Neuropathy risk rises continuously with sustained HbA1c elevation — there is no single threshold, but prolonged levels above the normal range cause oxidative stress, advanced glycation end-products, and microvascular damage to nerves.

HbA1c (glycated haemoglobin) is a measure of average blood glucose levels over the preceding two to three months. It is expressed as a percentage or in millimoles per mole (mmol/mol), with the latter being the standard unit used in the UK. Persistently elevated HbA1c is one of the most significant risk factors for the development of diabetic peripheral neuropathy — a form of nerve damage caused by prolonged exposure to high blood glucose.

There is no single HbA1c threshold at which neuropathy will definitively occur. The relationship between HbA1c and neuropathy risk is continuous: risk rises progressively with both the degree and duration of hyperglycaemia, and there is no universally 'safe' cut-off. The figure of 53 mmol/mol (7%) is a common UK treatment target (as recommended by NICE in guidelines NG17 and NG28), not a biological threshold — meaning that risk does not suddenly increase above this level, but rather accumulates over time with any sustained elevation above the normal range.

The landmark DCCT (Diabetes Control and Complications Trial) demonstrated that intensive glucose control reduced the incidence of neuropathy by approximately 60% in people with type 1 diabetes, with benefits persisting long after the trial ended — a phenomenon known as the 'legacy effect' (DCCT/EDIC). For type 2 diabetes, the UKPDS (UK Prospective Diabetes Study) similarly showed that better long-term glycaemic control significantly reduced microvascular complications, including neuropathy.

The mechanisms behind glucose-related nerve damage involve several pathways:

• Oxidative stress: Excess glucose generates free radicals that damage nerve cell membranes.

• Advanced glycation end-products (AGEs): These accumulate in nerve tissue, impairing function.

• Microvascular damage: High glucose injures the small blood vessels (vasa nervorum) that supply nerves, leading to ischaemia and nerve fibre loss.

Both the duration of elevated HbA1c and the degree of elevation matter. Someone with an HbA1c of 75 mmol/mol (9%) sustained over several years faces a considerably higher risk than someone with a transient, modest elevation. This underscores the importance of long-term glycaemic management rather than short-term correction alone. For a patient-facing explanation of HbA1c and UK units, the NHS website provides a helpful overview.

Recognising the Symptoms of Diabetic Peripheral Neuropathy

Diabetic peripheral neuropathy typically presents as tingling, burning pain, or numbness in a 'glove and stocking' distribution, though painless loss of protective sensation is equally common and increases the risk of unnoticed foot injury.

Diabetic peripheral neuropathy most commonly affects the feet and lower legs first, in a pattern often described as a 'glove and stocking' distribution. Symptoms can be subtle in the early stages, which is why many people are unaware they have developed nerve damage until a routine clinical assessment identifies it.

Common symptoms include:

• Tingling or 'pins and needles' in the feet or hands

• Burning or shooting pain, often worse at night

• Numbness or reduced sensation, making it difficult to feel temperature or pain

• Muscle weakness in the feet or legs

• Loss of balance or coordination, increasing the risk of falls

It is important to note that neuropathy does not always cause pain. In some individuals, the predominant feature is a progressive loss of protective sensation — meaning injuries, blisters, or pressure sores may go unnoticed, significantly increasing the risk of foot ulceration and, in severe cases, amputation.

Beyond peripheral neuropathy, chronically elevated HbA1c can also contribute to autonomic neuropathy, which affects the nerves controlling internal organs. This may present as:

• Gastroparesis (delayed stomach emptying)

• Postural hypotension (dizziness on standing)

• Bladder dysfunction or erectile dysfunction

Symptoms of neuropathy can sometimes be confused with other conditions. Important differentials include vitamin B12 deficiency (particularly relevant in people taking metformin long-term — see the management section), hypothyroidism, and peripheral arterial disease. A thorough clinical assessment, including appropriate blood tests, is therefore essential before attributing symptoms solely to diabetes.

A note on acute Charcot neuro-osteoarthropathy: a hot, red, swollen foot in a person with diabetes — even in the absence of significant pain — may indicate acute Charcot foot, which requires same-day assessment. This is discussed further in the 'When to Seek Medical Advice' section.

If you notice any of the above symptoms, particularly in the context of poorly controlled blood glucose, discuss them with your GP or diabetes care team promptly. Further information is available on the NHS diabetic neuropathy pages.

NICE Guidelines on HbA1c Targets and Neuropathy Prevention

NICE recommends HbA1c targets of 48 mmol/mol (6.5%) for most adults with diabetes, with annual structured foot assessments and same-day referral for active diabetic foot problems per NG19 and NG28.

NICE provides clear guidance on HbA1c targets for people living with diabetes, with the prevention of long-term complications — including neuropathy — as a central objective. According to NICE guideline NG28 (Type 2 Diabetes in Adults) and NICE guideline NG17 (Type 1 Diabetes in Adults), individualised HbA1c targets should be agreed between the patient and their clinician, taking into account factors such as age, comorbidities, hypoglycaemia risk, and personal preferences.

For most adults with type 2 diabetes managed with lifestyle or non-hypoglycaemic medications, NICE recommends an HbA1c target of 48 mmol/mol (6.5%). For those on medications that carry a hypoglycaemia risk (such as sulphonylureas or insulin), the target is typically 53 mmol/mol (7%). For type 1 diabetes, NICE recommends aiming for an HbA1c of 48 mmol/mol (6.5%) where this can be achieved safely without problematic hypoglycaemia. NICE (NG17) also recommends offering real-time or intermittently scanned continuous glucose monitoring (CGM) to adults with type 1 diabetes where appropriate, as this can support more stable glucose management.

NICE also recommends, in line with NICE guideline NG19 (Diabetic Foot Problems: Prevention and Management), that all people with diabetes receive a structured annual foot assessment as part of their diabetes review. The core elements of this assessment include:

• Testing for loss of protective sensation (using a 10 g monofilament)

• Examination of pedal pulses

• Inspection of skin integrity and foot deformity

Following assessment, feet should be formally risk-stratified as low, moderate, high, or active risk. This determines the frequency of follow-up and the appropriate care pathway:

• Low risk: Routine annual review in primary care

• Moderate or high risk: Referral to the foot protection team, with more frequent review

• Active diabetic foot problem (ulceration, infection, suspected Charcot foot, or critical ischaemia): Same-day referral to the multidisciplinary foot care service (MDFS)

NICE emphasises that achieving and maintaining HbA1c within the recommended range is the most effective strategy for reducing the risk of microvascular complications, including neuropathy, nephropathy, and retinopathy. Clinicians are advised to support patients in reaching their targets through structured education, medication optimisation, and lifestyle support.

Managing HbA1c to Reduce Your Risk of Nerve Complications

Maintaining HbA1c within target through lifestyle changes, optimised medication, and — for painful neuropathy — NICE-recommended agents such as duloxetine or gabapentin is the cornerstone of neuropathy prevention and symptom management.

Reducing and maintaining HbA1c within a safe target range is the cornerstone of neuropathy prevention and, in early stages, may help slow its progression. Management is multifaceted and involves both lifestyle modifications and, where necessary, pharmacological intervention.

Lifestyle measures that support better glycaemic control include:

• Dietary changes: Reducing refined carbohydrates and added sugars, increasing fibre intake, and following a balanced diet in line with the NHS Eatwell Guide

• Regular physical activity: At least 150 minutes of moderate-intensity exercise per week, which improves insulin sensitivity

• Weight management: Even modest weight loss (5–10% of body weight) can significantly improve HbA1c in type 2 diabetes

• Smoking cessation: Smoking worsens microvascular damage and compounds neuropathy risk

Pharmacological management should be guided by your diabetes care team. Medications such as metformin, SGLT-2 inhibitors, and GLP-1 receptor agonists are commonly used in type 2 diabetes and have evidence supporting cardiovascular and renal protection in addition to glucose lowering. For type 1 diabetes, optimising insulin regimens — including consideration of CGM or insulin pump therapy in line with NICE NG17 — can help achieve more stable glucose levels.

People taking metformin long-term should be aware that it can reduce the absorption of vitamin B12, which may itself cause or worsen neuropathy. The MHRA has issued safety advice on this. If you are taking metformin and develop neuropathic symptoms, anaemia, or other relevant features, your GP or diabetes team should consider checking your vitamin B12 level. If you suspect a side effect from any medication, you can report it via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk).

For those who already have established neuropathy, managing HbA1c remains important to prevent further deterioration. For painful diabetic neuropathy, NICE (CG173) recommends considering one of the following first-line options, chosen in discussion with the patient:

• Amitriptyline

• Duloxetine

• Gabapentin

• Pregabalin

Topical capsaicin cream may be considered for localised peripheral neuropathic pain in people who prefer to avoid or cannot tolerate oral treatments. Routine use of opioid analgesics is not recommended for neuropathic pain. These treatments address symptoms rather than the underlying nerve damage, but can significantly improve quality of life.

Foot care education — including daily inspection, appropriate footwear, and prompt reporting of any wounds — is also a vital component of ongoing management.

When to Seek Medical Advice About Neuropathy Symptoms

Seek same-day medical attention for a hot, red, or swollen foot (possible Charcot foot), infected foot wounds, or sudden severe limb symptoms; contact your GP promptly for new tingling, numbness, or pain disrupting daily life.

Knowing when to contact your GP or diabetes care team is an important aspect of self-management. Many people delay seeking advice about neuropathy symptoms, either because they are mild or because they assume they are an inevitable part of living with diabetes. However, early assessment and intervention can make a meaningful difference to outcomes.

Contact your GP or diabetes nurse promptly if you experience:

• New or worsening tingling, numbness, or burning in your feet or hands

• Pain that is disrupting your sleep or daily activities

• Any foot wound, blister, or ulcer that is not healing within a few days

• Sudden changes in sensation or unexplained weakness in the legs

• Dizziness when standing up, unexplained nausea, or bladder problems that may suggest autonomic involvement

Seek urgent medical attention (same day) if you notice:

• A foot wound that shows signs of infection (redness, swelling, warmth, discharge, or fever) — contact your GP, foot protection team, or multidisciplinary foot care service the same day, in line with NICE NG19

• A hot, red, or swollen foot — even without significant pain — as this may indicate acute Charcot neuro-osteoarthropathy, which requires same-day specialist assessment to prevent serious bone and joint damage

• Sudden severe pain or complete loss of sensation in a limb

• A foot that appears discoloured, cold, or has a foul odour — these may indicate serious infection or critical ischaemia

For any of the above urgent concerns, contact your GP surgery for a same-day appointment, your local multidisciplinary foot care service directly if you have been referred there previously, or call NHS 111 if you are unsure or it is outside normal hours. If you are concerned about a limb-threatening emergency, attend your nearest A&E department.

It is also worth noting that if your HbA1c has been consistently above target despite your best efforts, this is an important conversation to have with your care team. Medication adjustments, referral to a specialist diabetes service, or structured education programmes such as DESMOND (for type 2 diabetes) or DAFNE (for type 1 diabetes) may be appropriate.

Regular attendance at your annual diabetes review — which should include a structured foot assessment, HbA1c measurement, and kidney and eye assessments — remains one of the most effective ways to detect complications early and adjust your management plan accordingly. Do not wait for symptoms to become severe before seeking support. Further information is available on the NHS diabetic foot problems pages and through NICE guideline NG19.

Frequently Asked Questions